Vertaling van "risks and benefits " (Frans → Nederlands) :

Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women’s Health Initiative randomized controlled trial.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.

Article des assurances Vanbreda Risk & Benefits: Protection des installations critiques et/ou à risque (PDF)
Nieuwsartikel van de verzekeringen Vanbreda Risk & Benefits: Beveiliging van kritische en/of risicovolle installaties (PDF)

25. Berrington de Gonzalez A, Reeves G. Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits.
24. Berrington de Gonzalez A, Reeves G. Mammographic screening before age 50 years in the UK: comparison of the radiation risks with the mortality benefits.

63. Soumerai SB et al : Computer-based drug utilization review risk, benefit or boondoggle ?
63. Soumerai SB et al: Computer-based drug utilization review risk, benefit or boondoggle?

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.
DISCLOSURE NOTICE: The information contained in this release is as of September 1, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.
This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.

Heiss G, Wallace R, Anderson GL et al. Health risks and benefits 3 years after stoppin randomized treatment with estrogen and progestin.
Heiss G, Wallace R, Anderson GL et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

29. Law J, Faulkner K. Concerning the relationship between benefit and radiation risk, and cancers detected and induced, in a breast screening programme.
28. Law J, Faulkner K. Concerning the relationship between benefit and radiation risk, and cancers detected and induced, in a breast screening programme.